Different studies in SE randomized therapy in status epilepticus (RAISE) trial (NCT04391569), tuberous sclerosis complex (TSC), cyclin-dependent kinase-like 5 (CDKL5)-deficiency disorders, and protocadherin-19 (PCDH19)-related epilepsy are currently analyzing the effect of ganaxolone in these epilepsy subtypes (64). This evidence concerns the gene CDKL5 and epilepsy.